Immunoglobulin D (IgD) multiple myeloma (MM) is a rare plasma cell disorder constituting less than 2% of all MM cases. Survival of patients with IgD MM is generally shorter than that of patients with other types of monoclonal (M-) protein. We have retrospectively analyzed patients with IgD MM participating in clinical trials of the Czech Myeloma Group. Twenty-six IgD MM patients treated between 1996 and 2006 were identified, 14 (54%) men and 12 (46%) women. The median age was 61 years (range: 37-79 years). Ten of 26 patients (39%) were treated with first-line high-dose chemotherapy (HDCT) using melphalan 200 mg/m 2 followed by autologous stem cell transplantation (ASCT). Thirteen of 26 patients (50%) received conventional chemotherapy (CHT), mostly melphalan and prednisone or a vincristine/doxorubicin/dexamethasone (VAD) regimen. Treatment responses were evaluable for 23 of 26 (89%) patients. All HDCT patients had treatment responses, including seven patients (70%) with complete responses and three patients (30%) with partial responses. The median progressionfree survival was 18 months for HDCT patients and 20 months for CHT patients. The median overall survival (OS) for all patients was 34 months. The median OS for the HDCT group has not yet been reached (70% of the patients are still alive). In contrast, the median OS for CHT patients was only 16 months. The difference in OS between the two groups was statistically significant (P ¼ 0.005). In conclusion, the overall response rate for patients with IgD MM aged 65 years or less treated with HDCT and ASCT is similar to that seen in other MM types.
Introduction
Multiple myeloma (MM) is the second most frequent hematological malignancy. It is characterized by neoplastic proliferation of a single clone of plasma cells that usually produce a single serum monoclonal immunoglobulin (Mprotein). The most common type of M-protein found in MM is IgG followed by IgA and light chain only. IgD MM is a relatively rare plasma cell disorder affecting less than 2% of all MM patients. [1] [2] [3] It was first described by 4 who also described IgD as a new immunoglobulin class. 5, 6 IgD MM is more common in men, and in comparison with other MM types, the patients present at a younger age and more frequently develop renal failure, hypercalcemia, amyloidosis, extramedullary plasmacytomas, splenomegaly, hepatomegaly and generalized lymphadenopathy. [1] [2] [3] Because immunofixation for IgD is not routinely performed, the diagnosis is often either missed or misclassified as light-chain disease. In the majority of IgD MM cases, M-protein (60-90%) contains the l light chain. 7 The survival of patients with IgD MM is believed to be shorter than that of patients with other types of M-protein. 2, 7, 8 However, there are reports of long survival in patients with IgD MM treated with alkylating drugs, [9] [10] [11] interferon-a monotherapy 12 or autologous stem cell transplantation. 
Patients and methods

Staging and outcome evaluation
We used the Salmon-Durie staging system, 14 the International prognostic staging system 15 and the staging system for IgD MM developed by Shimamoto et al. 7 The latter staging system is based on two parameters-white blood cell count (WBC) and the light-chain type (low risk: WBC o7.0 and k-light chain; moderate risk: WBC47.0 and k-light chain; high risk: l-light chain).
For the analysis of treatment responses, progression-free survival (PFS) and overall survival (OS), the patients were divided into two groups: the HDCT group was treated with high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT); the conventional chemotherapy (CHT) group received treatment with conventional-dose chemotherapy.
Treatment responses were evaluated only in patients who had a follow-up longer than 6 weeks. Response to therapy, progression or relapse of disease were defined using the standard European Group for Blood and Marrow Transplantation (EBMT) criteria. 16 Overall treatment response was defined as a partial response or better. 17 Complete responses (CRs) were confirmed by negative serum immunofixation.
Statistical analysis
Comparisons between patients treated with HDCT and those treated with CHT were performed using the w 2 test or the Fisher's exact p-test. The Kaplan-Meier method was used to plot the survival curves. comparison was done using the log-rank test. The survival was also analyzed using the cox regression.
Results
Baseline characteristics
We identified 26 IgD MM patients treated in four Czech and three Slovak centers between 1996 and 2006. This represented 1.7% of all MM patients in the Czech Myeloma Group database. There were 14 men (54%) and 12 women (46%). The median age was 61 years (range: 37-79 years). The baseline characteristics of the patients are shown in Table 1 .
High-dose chemotherapy (melphalan 200 mg/m 2 ) followed by ASCT was used as first-line therapy in 10 of 26 patients (39%) (HDCT group). Of these ten patients, four patients (15%) later underwent a second ASCT for relapse/ progression.
Thirteen of 26 patients (50%) were treated with CHT (CHT group), mostly melphalan and prednisone or the VAD regimen.
The median age of the HDCT patients was 58 years (range: 37-64) and the median age of the CHT patients was 69 years (range: 49-79). With the exception of age, there were no statistically significant differences in baseline characteristics between the two groups.
Presenting symptoms of IgD MM
The most common presenting symptom was bone pain in 21 of 26 patients (81%). The most common diagnostic laboratory findings were elevated b 2 -microglobulin level in 20 of 26 patients (77%), elevated creatinine in 19 of 26 patients (73%) and anemia (hemoglobin o100 g/l) in 13 of 26 (50%) patients. Serum albumin level was lower than 35 g/l in only five of 26 patients (19%). No generalized lymphadenopathy, splenomegaly or plasma cell leukemization were reported as presenting features. There was only one patient with hepatomegaly at presentation and one patient with extraosseous plasma cell mass. In comparison to patients with other M-protein types in our database, IgD MM patients had lower serum M-protein concentrations and higher urinary M-protein concentrations, a characteristic that is responsible for the higher incidence of renal complications seen in IgD MM.
Bone marrow cytogenetics results were available for six patients (23%). Of these, one patient had t(14q32) and another had monosomy of chromosome 13. The myeloma cells isolated from the remaining four patients had normal karyotype.
Treatment outcomes
Treatment outcomes were evaluable for 23 of 26 patients (89%). We excluded three patients with follow-up shorter than 6 weeks-two of them died within 6 weeks of treatment initiation and one patient was lost to follow-up. Overall response rate (ORR) was 78%, with complete response (CR) in 10 of 23 patients (44%) and partial High-dose therapy changes prognosis of IgD multiple myeloma V Maisnar et al response (PR) in eight of 23 patients (40%). Interestingly, ORR in HDCT patients was 100% (10/10), including 70% (7/10) CRs and 30% (3/10) PRs. This is in contrast with ORR of 62% (8/13) in the CHT group, including 23% (3/13) CRs and 39% (5/13) PRs (Table 2 ). However, the difference was not statistically significant, probably due to the small number of patients. The median PFS was similar in the two groups: 18 months for HDCT and 20 months for CHT. The median OS for all patients was 34 months. The median OS for the HDCT patients has not yet been reached (at the time of analysis, seven of the ten patients were alive) and the median OS for the CHT patients was only 16 months (P ¼ 0.046). The Kaplan-Meier survival curves for both groups of patients are shown in Figure 1 .
Relapse or progression of MM were treated with a thalidomide-based regimen in five patients, a second ASCT was used in four patients and bortezomib monotherapy, in one patient. Thalidomide was used as second-line treatment in three patients (two with relapse after ASCT, one with progression after CHT). One of these patients had PR (33%). Two patients initially treated with CHT received thalidomide as third-line therapy, and one of them (50%) achieved a very good PR. We used a second ASCT in three patients who had achieved CR after the first ASCT and had relapsed after 10, 12 and 18 months, respectively. All three patients responded to the treatment (one CR, two PRs). A second ASCT was also used in one patient who had achieved PR after the first ASCT and progressed after 5 months. The latter patient paradoxically reached the best response to the second ASCT and subsequently maintained CR for 3 years. One patient was treated with bortezomib on progression after second ASCT but only had transient stabilization of the disease.
Fifteen of 25 patients (60%) had died by the time of analysis, including three out of ten HDCT patients (30%) and ten out of 13 CHT patients (77%). The most common causes of death were heart failure (27%), renal failure (27%), disease progression (20%) and infection (20%). Two patients died within 6 weeks of the start of treatment, one each of heart failure and renal failure. There were no peritransplant deaths. There were two patients who died of proven amyloidosis-related heart failure. One of them had echocardiographic findings of myocardial amyloidosis and the other patient had myocardial and renal amyloidosis confirmed on autopsy.
Discussion
The diagnosis of IgD MM can be elusive as the electrophoresis pattern in IgD MM is similar to that seen in lightchain MM. Usually, there is no obvious M-protein band or only a very weak band is observed. 3, 18 Therefore, IgD MM is thought to be commonly misdiagnosed as light-chain disease and immunofixation with anti-IgD and anti-IgE antibodies should always be performed before the diagnosis of light-chain disease is made. IgD M-protein should be sought especially in the setting of l light-chain production and l Bence-Jones proteinuria as IgD MM is associated with these findings. 3, 19 In a recent audit by the Czech Myeloma Group, 20 only 38% of laboratories had correctly diagnosed IgD-l MM. A similar experience from the French national external quality assessment was reported by Albarede et al. 21 The staging of IgD MM is controversial. The most popular MM clinical staging system proposed by Salmon and Durie 14 in 1976 did not include IgD MM because of its rarity. The more recent international prognostic staging system, which uses only two prognostic factors, serum b 2 -microglobulin and albumin, 15 is also difficult to apply in IgD MM because practically all patients with IgD MM have elevated b 2 -microglobulin and often also reduced albumin because of renal impairment. Shimamoto et al. proposed a staging system for IgD MM based on their analysis of 165 patients treated with conventional-dose chemotherapy. They identified two independent adverse prognostic risk factors for IgD MM: l light-chain subtype and WBC X7 Â 10 9 /l. However, Blade et al. 8 did not find statistically significant differences in treatment responses or survival between IgD MM patients with l light chain versus k light chain. In the Shimamoto staging system, the presence of l light chain is the only criterion for adverse prognosis. Because this type of light chain is present in 60-90% of patients with IgD MM, the applicability of this staging system for the stratification of patients according to their risk is limited. In our study, all patients treated with HDCT had IgD-l M-protein, but they still achieved High-dose therapy changes prognosis of IgD multiple myeloma V Maisnar et al treatment responses similar to those seen in more common MM subtypes. Thus, our results confirm other studies that have shown that the use of HDCT can significantly improve poor prognosis attributed to IgD MM. [22] [23] [24] Nevertheless, even among our patients, there were two long-term survivors after treatment with CHT. It needs to be pointed out that all the above studies, including ours, are retrospective and therefore subject to patient selection bias and lack of intention-to-treat analysis. In our study, the difference in OS between the two groups with similar PFS can be due to several factors. The patient cohorts were small and the HDCT patients were somewhat younger. Also, in our experience, the treatment of relapse/progression after standard-dose chemotherapy is more difficult than that after HDCT. No randomized studies of HDCT in IgD MM have been published, and they are unlikely to be carried out in the foreseeable future due to the small number of patients with IgD MM and overall rapid advances in the treatment of MM. At present, there are limited data on the results of biologic/targeted treatments for IgD. Because drugs of this type usually have lower nephrotoxicity and cardiotoxicity than CHT agents, it may be desirable to employ them early in IgD MM, which is associated with a high rate of amyloidosis (up to 50% at diagnosis). 25, 26 In our cohort, heart failure and renal failure were the most common causes of death. One of our patients died during induction chemotherapy due to advanced myocardial amyloidosis that was proved on autopsy.
In conclusion, we have found that the treatment outcomes with HDCT followed by ASCT in patients with IgD MM are similar to those achieved in other MM subtypes despite the traditional association of IgD Mprotein with poor prognosis. However, heart and renal complications are common in IgD MM patients due to a high prevalence of amyloidosis.
